Assessment of QTc prolongation following thioridazine withdrawal in a developmentally disabled population [2]
Journal of Clinical Psychopharmacology, ISSN: 0271-0749, Vol: 23, Issue: 3, Page: 314-315
2003
- 2Citations
- 4Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations2
- Citation Indexes2
- CrossRef1
- Captures4
- Readers4
Letter Description
Indications:15 patients with coexisting developmental disability. Patients:15 patients (12 males, 3 females; aged 42.7 years, range 27-57 years). Follow-up: 8 weeks postdiscontinuation; 2 patients followed every 6 months thereafter. TypeofStudy:QTc interval prolongation associated with Melleril withdrawal in developmentally disable patients was assessed. DosageDuration:Dosage and duration not stated. Results:Even with the increased QTc prolongation interval, 2 persons' intervals remained less than 400 msec. Another individual was on the cutoff, and the interval increased only slightly. The remaining 2 individuals experienced more marked increases (408 vs. 448 and 401 vs. 456 msec). AdverseEffects:5 patients experienced increases in QTc interval prolongation times after discontinuation. FreeText:Tests done: electrocardiogram monitoring.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0038384117&origin=inward; http://dx.doi.org/10.1097/00004714-200306000-00014; http://www.ncbi.nlm.nih.gov/pubmed/12826995; http://journals.lww.com/00004714-200306000-00014; https://dx.doi.org/10.1097/00004714-200306000-00014; https://journals.lww.com/psychopharmacology/Citation/2003/06000/Assessment_of_QTc_Prolongation_Following.14.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know